These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Myocardial PKC beta2 and the sensitivity of Na/K-ATPase to marinobufagenin are reduced by cicletanine in Dahl hypertension. Fedorova OV; Talan MI; Agalakova NI; Droy-Lefaix MT; Lakatta EG; Bagrov AY Hypertension; 2003 Mar; 41(3):505-11. PubMed ID: 12623951 [TBL] [Abstract][Full Text] [Related]
6. Endogenous ligand of alpha(1) sodium pump, marinobufagenin, is a novel mediator of sodium chloride--dependent hypertension. Fedorova OV; Talan MI; Agalakova NI; Lakatta EG; Bagrov AY Circulation; 2002 Mar; 105(9):1122-7. PubMed ID: 11877366 [TBL] [Abstract][Full Text] [Related]
7. Brain ouabain stimulates peripheral marinobufagenin via angiotensin II signalling in NaCl-loaded Dahl-S rats. Fedorova OV; Agalakova NI; Talan MI; Lakatta EG; Bagrov AY J Hypertens; 2005 Aug; 23(8):1515-23. PubMed ID: 16003178 [TBL] [Abstract][Full Text] [Related]
8. Plasma level of the endogenous sodium pump ligand marinobufagenin is related to the salt-sensitivity in men. Fedorova OV; Lakatta EG; Bagrov AY; Melander O J Hypertens; 2015 Mar; 33(3):534-41; discussion 541. PubMed ID: 25479026 [TBL] [Abstract][Full Text] [Related]
9. Marinobufagenin in Urine: A Potential Marker of Predisposition to Ethanol and a Target for Spironolactone. Kashkin VA; Shekunova EV; Egorov AY; Bagrov AY Curr Hypertens Rev; 2018; 14(1):35-38. PubMed ID: 29437012 [TBL] [Abstract][Full Text] [Related]
10. Antibody against Na/K-ATPase Inhibitor Lowers Blood Pressure and Increases Vascular Fli1 in Experimental Preeclampsia. Agalakova NI; Reznik VA; Nadei OV; Ershov IA; Rassokha OS; Vasyutina ML; Ivanov DO; Adair CD; Galagudza MM; Bagrov AY Am J Hypertens; 2020 May; 33(6):514-519. PubMed ID: 31713584 [TBL] [Abstract][Full Text] [Related]
12. Antibody to Marinobufagenin Reverses Placenta-Induced Fibrosis of Umbilical Arteries in Preeclampsia. Fedorova OV; Ishkaraeva VV; Grigorova YN; Reznik VA; Kolodkin NI; Zazerskaya IE; Zernetkina V; Agalakova NI; Tapilskaya NI; Adair CD; Lakatta EG; Bagrov AY Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30104471 [TBL] [Abstract][Full Text] [Related]
13. Involvement of marinobufagenin in a rat model of human preeclampsia. Vu HV; Ianosi-Irimie MR; Pridjian CA; Whitbred JM; Durst JM; Bagrov AY; Fedorova OV; Pridjian G; Puschett JB Am J Nephrol; 2005; 25(5):520-8. PubMed ID: 16179779 [TBL] [Abstract][Full Text] [Related]
14. Endogenous sodium pump inhibitors and age-associated increases in salt sensitivity of blood pressure in normotensives. Anderson DE; Fedorova OV; Morrell CH; Longo DL; Kashkin VA; Metzler JD; Bagrov AY; Lakatta EG Am J Physiol Regul Integr Comp Physiol; 2008 Apr; 294(4):R1248-54. PubMed ID: 18287222 [TBL] [Abstract][Full Text] [Related]
15. Endogenous cardiotonic steroids and differential patterns of sodium pump inhibition in NaCl-loaded salt-sensitive and normotensive rats. Bagrov AY; Agalakova NI; Kashkin VA; Fedorova OV Am J Hypertens; 2009 May; 22(5):559-63. PubMed ID: 19229192 [TBL] [Abstract][Full Text] [Related]
16. Marinobufagenin, an endogenous ligand of alpha-1 sodium pump, is a marker of congestive heart failure severity. Fridman AI; Matveev SA; Agalakova NI; Fedorova OV; Lakatta EG; Bagrov AY J Hypertens; 2002 Jun; 20(6):1189-94. PubMed ID: 12023690 [TBL] [Abstract][Full Text] [Related]